Zynex (ZYXI) investor relations material

Executive summary

• New management and board members have been appointed, including leaders in sales, legal, compliance, regulatory, HR, billing, and strategic marketing, as well as two new directors overseeing audit and strategic alternatives.

• A three-part turnaround strategy is underway: compliance, liquidity improvement, and revenue/cash flow enhancement.

• Major impairment charges of $30.7M were recorded in Q3 2025 related to the ZMS subsidiary.

• Significant operational disruptions due to Tricare payment suspension and workforce reductions.

• Province LLC and a Special Committee were engaged to evaluate strategic and financing alternatives, with no transaction identified yet.

Financial highlights

• Net revenue for Q3 2025 was $13.4M, down from $50M in Q3 2024, mainly due to Tricare payment suspension and payer claim issues.

• Gross profit was $8.1M (60% margin), compared to $39.8M (80% margin) in Q3 2024.

• Net loss for Q3 2025 was $42.9M ($1.42 per share), versus net income of $2.4M in Q3 2024.

• Adjusted EBITDA loss was $12.3M, compared to positive $5.1M in Q3 2024.

• Cash and cash equivalents stood at $13.3M as of September 30, 2025.

Outlook and guidance

• Management is focused on resolving government investigations, recapitalizing, and improving operational performance.

• Substantial doubt exists about the ability to continue as a going concern for 12 months from the financial statement issuance date.

• The company is exploring restructuring and financing alternatives, including discussions with creditors.

• No specific financial guidance provided.

• Early signs of stabilization in order volumes and improved sales force productivity are noted.